Senior Account Manager, France at Schrödinger

France

Schrödinger Logo
Not SpecifiedCompensation
Senior (5 to 8 years)Experience Level
Full TimeJob Type
UnknownVisa
Biotech, Pharmaceutical, Life Sciences, ChemicalIndustries

Requirements

  • At least three years of experience in account management, business development, or consulting in the chemical and/or pharmaceutical industries
  • Advanced degree in life sciences (knowledge of molecular modeling or materials science is a plus)
  • Some familiarity with computational chemistry software
  • Fluency in English. Fluency in French preferred

Responsibilities

  • Identify, qualify, and develop new business opportunities with a primary focus on the biotech sector, while also engaging with pharmaceutical and life sciences organizations
  • Manage and grow existing accounts
  • Collaborate with the EU+ team to develop business and marketing strategies to target specific customer segments
  • Produce timely and accurate business reports and revenue forecasts
  • Travel to customers and conferences

Skills

Account Management
Business Development
Sales
Computational Chemistry Software
Molecular Modeling
Materials Science
Revenue Forecasting
Customer Relationship Management
French

Schrödinger

Computational platform for biopharmaceutical research

About Schrödinger

Schrödinger provides a computational platform that aids in the research efforts of biopharmaceutical companies, academic institutions, and government laboratories around the world. Their platform offers advanced computational tools that help in drug discovery and development across various therapeutic areas. Schrödinger's products work by using sophisticated algorithms and simulations to predict how different compounds will interact, which can significantly speed up the research process. Unlike many competitors, Schrödinger not only licenses its software but also engages in collaborative research and drug discovery programs, allowing for a more integrated approach to scientific research. The company's goal is to enhance scientific research and development through its platform, ultimately leading to the discovery of new drugs and therapies.

New York City, New YorkHeadquarters
1990Year Founded
$362.7MTotal Funding
IPOCompany Stage
Government & Public Sector, Enterprise Software, BiotechnologyIndustries
501-1,000Employees

Benefits

Health Insurance
Dental Insurance
Vision Insurance
401(k) Company Match
401(k) Retirement Plan
Flexible Work Hours
Remote Work Options
Paid Vacation
Parental Leave

Risks

Recursion and Exscientia merger creates strong AI-driven drug discovery competitor.
Avicenna's independent expansion could lead to competitive tensions with Schrödinger.
High R&D costs may strain resources despite Gates Foundation's $10M grant.

Differentiation

Schrödinger's platform supports diverse clients, including biopharma, academia, and government labs.
The company excels in rapid drug discovery, exemplified by SGR-1505's swift development.
Schrödinger's collaboration with Avicenna enhances medicinal chemistry through machine learning.

Upsides

$19.5M Gates Foundation grant boosts platform for neglected diseases, expanding market reach.
Predictive toxicology tools initiative could lead to safer, efficient drug development.
SGR-1505 discovery showcases ability to reduce drug discovery timelines significantly.

Land your dream remote job 3x faster with AI